Immunovia publ AB (IMMNOV) - Total Assets
Based on the latest financial reports, Immunovia publ AB (IMMNOV) holds total assets worth Skr65.70 Million SEK (≈ $7.07 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Immunovia publ AB debt service capacity to assess how comfortably operating cash covers total debt obligations.
Immunovia publ AB - Total Assets Trend (2012–2025)
This chart illustrates how Immunovia publ AB's total assets have evolved over time, based on quarterly financial data. See IMMNOV book value for net asset value and shareholders' equity analysis.
Immunovia publ AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Immunovia publ AB's total assets of Skr65.70 Million consist of 91.2% current assets and 8.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 87.8% |
| Accounts Receivable | Skr1.31 Million | 1.5% |
| Inventory | Skr119.00K | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr6.72 Million | 7.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Immunovia publ AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Immunovia publ AB worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunovia publ AB's current assets represent 91.2% of total assets in 2025, an increase from 26.1% in 2012.
- Cash Position: Cash and equivalents constituted 87.8% of total assets in 2025, up from 23.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 73.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 7.6% of total assets.
Immunovia publ AB Competitors by Total Assets
Key competitors of Immunovia publ AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Immunovia publ AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.05 | 2.84 | 8.61 |
| Quick Ratio | 3.04 | 2.84 | 8.57 |
| Cash Ratio | 0.00 | 2.59 | 0.00 |
| Working Capital | Skr39.32 Million | Skr26.77 Million | Skr348.02 Million |
Immunovia publ AB - Advanced Valuation Insights
This section examines the relationship between Immunovia publ AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 167.0% |
| Total Assets | Skr88.21 Million |
| Market Capitalization | $13.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immunovia publ AB's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Immunovia publ AB's assets grew by 167.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunovia publ AB (2012–2025)
The table below shows the annual total assets of Immunovia publ AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr88.21 Million ≈ $9.49 Million |
+166.97% |
| 2024-12-31 | Skr33.04 Million ≈ $3.56 Million |
-66.52% |
| 2023-12-31 | Skr98.68 Million ≈ $10.62 Million |
-67.17% |
| 2022-12-31 | Skr300.59 Million ≈ $32.35 Million |
-39.13% |
| 2021-12-31 | Skr493.81 Million ≈ $53.14 Million |
-25.31% |
| 2020-12-31 | Skr661.18 Million ≈ $71.15 Million |
+57.66% |
| 2019-12-31 | Skr419.37 Million ≈ $45.13 Million |
-12.15% |
| 2018-12-31 | Skr477.38 Million ≈ $51.37 Million |
+90.37% |
| 2017-12-31 | Skr250.77 Million ≈ $26.99 Million |
-11.52% |
| 2016-12-31 | Skr283.41 Million ≈ $30.50 Million |
+209.71% |
| 2015-12-31 | Skr91.51 Million ≈ $9.85 Million |
+135.40% |
| 2014-12-31 | Skr38.87 Million ≈ $4.18 Million |
+420.70% |
| 2013-12-31 | Skr7.47 Million ≈ $803.42K |
+149.05% |
| 2012-12-31 | Skr3.00 Million ≈ $322.60K |
-- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.